Dose-Dependent Aggregation Behavior Evaluation is a critical analytical service designed to assess the propensity of therapeutic proteins, monoclonal antibodies (mAbs), fusion proteins, and other biologics to form aggregates across a range of concentrations. Protein aggregation poses significant risks to drug safety, efficacy, and stability, making this evaluation indispensable for biopharmaceutical development, formulation optimization, and regulatory compliance.
We deploy orthogonal, state-of-the-art technologies to deliver robust, reproducible aggregation data:
| Technology | Key Metrics | Detection Limits |
|---|---|---|
| SEC-HPLC | Monomer/oligomer/aggregate ratio | ≥0.1% aggregates (w/w) |
| Dynamic Light Scattering (DLS) | Hydrodynamic diameter (Z-average) | 0.3 nm - 10 µm |
| Analytical Ultracentrifugation (AUC) | Sedimentation coefficients, mass distribution | 0.01% aggregates |
| Micro-Flow Imaging (MFI) | Particle count, morphology (e.g., fibers, gels) | ≥1 µm particles |
| FTIR Spectroscopy | Secondary structure changes (β-sheet formation) | Conformational shifts ≥5% |
| Differential Scanning Calorimetry (DSC) | Thermal unfolding (Tm) and aggregation onset | ±0.1°C precision |
Study Design Consultation
Experimental Execution
Comprehensive Report
For more information on our Dose-Dependent Aggregation Behavior Evaluation services or to discuss your specific biopharmaceutical project requirements, please contact us today.
Holiday savings valid through 1/31/2026:
10% OFF All Testing Services
Enjoy an exclusive 10% discount on all our testing services — helping you achieve accurate results while saving costs.
(Use code: HOLIDAY10TS)
Big Savings on Product Orders
Place your orders now and unlock incredible discounts:
All discounts applied at checkout (shipping fees not included in order total).
* The discount amount applies to a single purchase order.